PROMIS NEUROSCIENCES INC. Capital Expenditures
PROMIS NEUROSCIENCES INC. (PMN) reported Capital Expenditures of $1.98 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2024-04-01
- PROMIS NEUROSCIENCES INC. payments to acquire property, plant, and equipment for the quarter ending 2022-12-31 was -$43.00, a 100.89% decline year-over-year.
- PROMIS NEUROSCIENCES INC. payments to acquire property, plant, and equipment for the quarter ending 2022-09-30 was -$24.00.
- PROMIS NEUROSCIENCES INC. payments to acquire property, plant, and equipment for the quarter ending 2022-06-30 was -$9.00.
- PROMIS NEUROSCIENCES INC. payments to acquire property, plant, and equipment for the quarter ending 2022-03-31 was $2.06K.
- PROMIS NEUROSCIENCES INC. payments to acquire property, plant, and equipment for fiscal 2022 was $1.98K, a 67.22% decline from fiscal 2021.
- PROMIS NEUROSCIENCES INC. payments to acquire property, plant, and equipment for fiscal 2021 was $6.04K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$43.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$67.00 derived: sum of 2 quarters · filed 2024-04-01 | -$76.00 derived: sum of 3 quarters · filed 2024-04-01 | $1.98K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$24.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$33.00 derived: sum of 2 quarters · filed 2023-11-14 | $2.02K 10-Q · filed 2023-11-14 | $6.88K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$9.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $2.05K 10-Q · filed 2023-08-14 | $6.91K derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $2.06K 10-Q · filed 2023-05-15 | $6.91K derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $4.86K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $6.04K 10-K · filed 2023-03-08 | ||
| 2021-09-30 | $1.19K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |